EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 20 April 2021 Christopher Mills, Chairman, sold a total of 3,963,591 ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at an average price of 80 pence per Ordinary Share.

30th Mar 2021

Final results for the year ended 31 December 2020

Further to the announcement on 5 August 2020.

3rd Mar 2021

Investor briefing 30 March 2021.

12th Jan 2021

EKF Diagnostics confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations.

EKF Diagnostics declares the distribution of shares in Trellus Health Limited.

10th Dec 2020

A General Meeting was held to seek shareholder approval to distribute the company's holding in Trellus Health Limited.

Kantaro Biosciences, LLC has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.